Contribution of glutathione peroxidase 1 (Pro200Leu) single nucleotide polymorphism and serum homocysteine levels in the risk of acute myocardial infarction in Egyptians
Tóm tắt
Oxidative stress is among the most common risk factors in the pathogenesis of acute myocardial infarction (AMI). Glutathione peroxidase 1 enzyme coded by the GPX1 gene plays an essential role in reducing oxidative stress. Previous studies correlated the GPX1 (Pro200Leu) single nucleotide polymorphism (SNP) with AMI incidence. Elevated homocysteine (Hcy) levels induce oxidative stress and are considered an independent risk factor for AMI. Evidence showed a complex relationship between Hcy and GPx-1 activity. This study examined the association of the common (Pro200Leu) SNP in GPX1 with AMI incidence in an Egyptian population. This study is the first to check this association in an Egyptian population. Moreover, the association between serum Hcy and the incidence of AMI was checked, and the novelty was to statistically correlate GPX1 Pro200Leu genotypes with serum Hcy levels in patients and control subjects. Hundred control subjects and hundred and twenty AMI patients were genotyped using PCR-RFLP analysis. An ELISA was used to measure serum Hcy levels. The GPX1 (Pro200Leu) genotype distribution and allele frequency were not significantly different between patients and control subjects (P = 0.60 and P = 0.62, respectively). Serum levels of Hcy were significantly elevated in patients compared to control subjects (P ≤ 0.0001). However, no significant difference was observed in serum Hcy levels among different GPX1 genotypes in neither patients nor control subjects. The minor T allele of GPX1 Pro200Leu is not associated with AMI risk in this Egyptian population. However, high homocysteine serum levels might contribute independently to the risk of AMI. Finally, Hcy levels were not significantly different in homozygous minor TT compared to homozygous wild CC.
Tài liệu tham khảo
Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW (2020) Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation 141:e139–e596
Saleh M and Ambrose J A (2018) Understanding myocardial infarction. F1000Res 7:
Griendling KK, FitzGerald GA (2003) Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108:1912–1916
Shiomi T, Tsutsui H, Matsusaka H, Murakami K, Hayashidani S, Ikeuchi M, Wen J, Kubota T, Utsumi H, Takeshita A (2004) Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 109:544–549
Lubos E, Loscalzo J, Handy DE (2011) Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 15:1957–1997
Jefferies S, Kote-Jarai Z, Goldgar D, Houlston R, Frazer-Williams MJ, A'Hern R, Eeles R, Henk J, Gore M, Rhys-Evans P, Archer D, Bishop K, Solomon E, Hodgson S, McGurk M, Hibbert J, O'Connell M, Partridge M, Chevretton E, Calman F, Saunders M, Shotton K, Brown A, Whittaker S, Foulkes W (2005) Association between polymorphisms of the GPX1 gene and second primary tumours after index squamous cell cancer of the head and neck. Oral Oncol 41:455–461
Toussaint O, Houbion A, Remacle J (1993) Relationship between the critical level of oxidative stresses and the glutathione peroxidase activity. Toxicology 81:89–101
Suzen HS, Gucyener E, Sakalli O, Uckun Z, Kose G, Ustel D, Duydu Y (2010) CAT C-262T and GPX1 Pro198Leu polymorphisms in a Turkish population. Mol Biol Rep 37:87–92
Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M, Cambien F, Meyer J, Lackner KJ (2003) Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 349:1605–1613
Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, Loscalzo J (1997) Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272:17012–17017
Hamanishi T, Furuta H, Kato H, Doi A, Tamai M, Shimomura H, Sakagashira S, Nishi M, Sasaki H, Sanke T, Nanjo K (2004) Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in Japanese type 2 diabetic patients. Diabetes 53:2455–2460
Ravn-Haren G, Olsen A, Tjønneland A, Dragsted LO, Nexø BA, Wallin H, Overvad K, Raaschou-Nielsen O, Vogel U (2006) Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study. Carcinogenesis 27:820–825
Forgione MA, Weiss N, Heydrick S, Cap A, Klings ES, Bierl C, Eberhardt RT, Farber HW, Loscalzo J (2002) Cellular glutathione peroxidase deficiency and endothelial dysfunction. Am J Physiol Heart Circ Physiol 282:H1255–H1261
Chen H, Yu M, Li M, Zhao R, Zhu Q, Zhou W, Lu M, Lu Y, Zheng T, Jiang J, Zhao W, Xiang K, Jia W, Liu L (2012) Polymorphic variations in manganese superoxide dismutase (MnSOD), glutathione peroxidase-1 (GPX1), and catalase (CAT) contribute to elevated plasma triglyceride levels in Chinese patients with type 2 diabetes or diabetic cardiovascular disease. Mol Cell Biochem 363:85–91
Forsberg L, de Faire U, Marklund SL, Andersson PM, Stegmayr B, Morgenstern R (2000) Phenotype determination of a common Pro-Leu polymorphism in human glutathione peroxidase 1. Blood Cells Mol Dis 26:423–426
Ramprasath T, Murugan PS, Kalaiarasan E, Gomathi P, Rathinavel A, Selvam GS (2012) Genetic association of glutathione peroxidase-1 (GPx-1) and NAD(P)H:quinone oxidoreductase 1 (NQO1) variants and their association of CAD in patients with type-2 diabetes. Mol Cell Biochem 361:143–150
Sergeeva TV, Chistiakov DA, Kobalava ZD, Moiseev VS (2001) Polymorphism of catalase and glutathione peroxidase genes in macrovascular complications in patients with non-insulin-dependent diabetes mellitus and hypertension. Genetika 37:418–421
Malinow MR, Bostom AG, Krauss RM (1999) Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 99:178–182
Perła-Kaján J, Twardowski T, Jakubowski H (2007) Mechanisms of homocysteine toxicity in humans. Amino Acids 32:561–572
Herrmann W (2006) Significance of hyperhomocysteinemia. Clin Lab 52:367–374
Jakubowski H (2006) Pathophysiological consequences of homocysteine excess. J Nutr 136:1741S–1749S
Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, Jacobsen DW (2001) Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation. J Biol Chem 276:46896–46904
Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ, Goodfellow J (2002) Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation 105:22–26
Bagi Z, Ungvari Z, Koller A (2002) Xanthine oxidase-derived reactive oxygen species convert flow-induced arteriolar dilation to constriction in hyperhomocysteinemia: possible role of peroxynitrite. Arterioscler Thromb Vasc Biol 22:28–33
Petras M, Tatarkova Z, Kovalska M, Mokra D, Dobrota D, Lehotsky J, Drgova A (2014) Hyperhomocysteinemia as a risk factor for the neuronal system disorders. J Physiol Pharmacol 65:15–23
Handy DE, Zhang Y, Loscalzo J (2005) Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem 280:15518–15525
Weiss N, Heydrick S, Zhang YY, Bierl C, Cap A, Loscalzo J (2002) Cellular redox state and endothelial dysfunction in mildly hyperhomocysteinemic cystathionine beta-synthase-deficient mice. Arterioscler Thromb Vasc Biol 22:34–41
Durmaz A, Dikmen N (2007) Homocysteine effects on cellular glutathione peroxidase (GPx-1) activity under in vitro conditions. J Enzyme Inhib Med Chem 22:733–738
Schnabel R, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Torzewski M, Lubos E, Bickel C, Cambien F, Tiret L, Münzel T, Blankenberg S (2005) Glutathione peroxidase-1 and homocysteine for cardiovascular risk prediction: results from the AtheroGene study. J Am Coll Cardiol 45:1631–1637
Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE (2009) Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 8:113–117
Dai S, Long Y (2015) Genotyping analysis using an RFLP assay. Methods Mol Biol 1245:91–99
Nemoto M, Nishimura R, Sasaki T, Hiki Y, Miyashita Y, Nishioka M, Fujimoto K, Sakuma T, Ohashi T, Fukuda K, Eto Y, Tajima N (2007) Genetic association of glutathione peroxidase-1 with coronary artery calcification in type 2 diabetes: a case control study with multi-slice computed tomography. Cardiovasc Diabetol 6:23
Cheng ML, Chen CM, Ho HY, Li JM, Chiu DT (2009) Effect of acute myocardial infarction on erythrocytic glutathione peroxidase 1 activity and plasma vitamin e levels. Am J Cardiol 103:471–475
Shuvalova YA, Kaminnyi AI, Meshkov AN, Kukharchuk VV (2010) Pro198Leu polymorphism of GPx-1 gene and activity of erythrocytic glutathione peroxidase and lipid peroxidation products. Bull Exp Biol Med 149:743–745
Lei C, Niu XL, Wei J, Zhu JH, Zhu Y (2010) Polymorphisms in the glutathione peroxidase-1 gene associated with increased risk of Keshan disease. Zhonghua Yu Fang Yi Xue Za Zhi 44:617–621
Biasioli S, Schiavon R (2000) Homocysteine as a cardiovascular risk factor. Blood Purif 18:177–182
Ansari R, Mahta A, Mallack E, Luo JJ (2014) Hyperhomocysteinemia and neurologic disorders: a review. J Clin Neurol 10:281–288
Baszczuk A, Kopczyński Z (2014) Hyperhomocysteinemia in patients with cardiovascular disease. Postepy Hig Med Dosw (Online) 68:579–589
Maldonado C, Soni CV, Todnem ND, Pushpakumar S, Rosenberger D, Givvimani S, Villafane J, Tyagi SC (2010) Hyperhomocysteinemia and sudden cardiac death: potential arrhythmogenic mechanisms. Curr Vasc Pharmacol 8:64–74
Ganguly P, Alam SF (2015) Role of homocysteine in the development of cardiovascular disease. Nutr J 14:6
Lentz SR (2005) Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 3:1646–1654
Heinecke JW, Rosen H, Suzuki LA, Chait A (1987) The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 262:10098–10103
Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I (1991) Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324:1149–1155
Naureen A, Munazza B, Shaheen R, Khan SA, Fatima F (2012) Serum homocysteine as a risk factor for coronary heart disease. J Ayub Med Coll Abbottabad 24:59–62
Shenoy V, Mehendale V, Prabhu K, Shetty R, Rao P (2014) Correlation of serum homocysteine levels with the severity of coronary artery disease. Indian J Clin Biochem 29:339–344
Amiri Majd A, Rezaei M, Goodarzi M, Homayoonfar S (2007) Some biomarkers in acute myocardial infarction. J Res Health Sci 7:11–19
Dayal S, Brown KL, Weydert CJ, Oberley LW, Arning E, Bottiglieri T, Faraci FM, Lentz SR (2002) Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. Arterioscler Thromb Vasc Biol 22:1996–2002
